Utilization of a CMV T Cell Immunity Panel in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

被引：0
|
作者：
Ray, A. [1 ]
Garner, B. [1 ]
Klein, C. [1 ]
机构：
[1] Piedmont Transplant Inst, Atlanta, GA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B84
引用
收藏
页码：S793 / S793
页数：1
相关论文
共 50 条
  • [21] Primary CMV Infections Are Common in Kidney Transplant Recipients after 6 Months Valganciclovir Prophylaxis.
    Helantera, Ilkka
    Kyllonen, Lauri
    Lautenschlager, Irmeli
    Salmela, Kaija
    Koskinen, Petri
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 206 - 207
  • [22] Is CMV Prophylaxis Necessary in CMV Low-Risk Liver Transplant Recipients?
    Fleming, J. N.
    Bowman, L.
    Truscott, C.
    Pilch, N.
    Taber, D.
    Pote, L.
    Powderly, A.
    Mathur, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 474 - 474
  • [23] Universal Prophylaxis with Oral Valganciclovir Significantly Reduces First Year CMV Disease in Kidney Transplant Recipients
    Wu, M. -J.
    Tu, P. -T.
    TRANSPLANTATION, 2012, 94 (10) : 531 - 531
  • [24] Increased Incidence of Leucopenia With FDA Approved Valganciclovir Dosing for CMV Prophylaxis in Pediatric Kidney Transplant Recipients
    Bhatnagar, S.
    Palma, K.
    Palmer, J.
    Baluarte, J.
    Amaral, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 501 - 501
  • [25] Valganciclovir prophylaxis for 6 months prevents CMV-induced disease in 96% of kidney transplant recipients
    Cantarovich, Diego
    Giral, Magali
    Dantal, Jacques
    Blacho, Gilles
    Soulillou, Jean-Paul
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 90 - 91
  • [26] Valganciclovir followed by CMV hyperimmune globulin compared to valganciclovir for 200 days in abdominal organ transplant recipients at high risk for CMV infection.
    Fleming, James
    Taber, Dave
    Pilch, Nicole
    Nadig, Satish
    McGillicuddy, John
    Bratton, Charles
    Baliga, Prabhakar
    Chavin, Kenneth D.
    PHARMACOTHERAPY, 2016, 36 (12): : E307 - E307
  • [27] CMV Pneumonitis After Discontinuation of Prophylaxis Therapy Guided by CMV T-cell Immunity Panel
    Nguyen, M.
    Pham, C.
    Pierce, B. J.
    Yau, S. W.
    Goodarzi, A.
    Youssef, J. G.
    Huang, H. J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S417 - S418
  • [28] Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection
    Boutolleau, David
    Deback, Claire
    Bressollette-Bodin, Celine
    Varnous, Shaida
    Dhedin, Nathalie
    Barrou, Benoit
    Vernant, Jean-Paul
    Gandjbakhch, Iradj
    Imbert-Marcille, Berthe-Marie
    Agut, Henri
    ANTIVIRAL RESEARCH, 2009, 81 (02) : 174 - 179
  • [29] Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis
    Thielke, J.
    Jasiak, N.
    Hilal, N.
    Salah, S.
    Benedetti, E.
    West-Thielke, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 692 - 693
  • [30] Unquantified Blips Lead to CMV Slips - Post Transplant CMV Monitoring in High Risk Kidney Transplant Recipients
    Payne, A. T.
    Timpone, J. G.
    Gilbert, A.
    Thomas, B.
    Lindner, B. K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 634 - 634
12345